Sunday , September 25 2016

From the Editor

September, 2016

  • 24 September

    Sept. 24, 2016

    dave

    The standard treatment for uncontrolled uterine bleeding has been emergency care where a woman undergoes transfusion dilatation curettage and then a hysterectomy. This is a severe procedure with a long recovery time and long-lasting complications. Over the past few years, a lot of women have been treated with endometrialhydrothermal ablation, a much less invasive procedure with ...

    Read More »

Latest Articles

September, 2016

Test Your Knowledge

Question #852

Please refer to the graph below and indicate the parameter that best describes Curve 4.

Issue852TYK

Correct

Answer:  4 - Insulin Secretion

Educational Critique:  Generally, type 2 diabetes is characterized by increasing insulin resistance at target tissues, although the underlying reasons for this increasing resistance are not yet well understood. Insulin-dependent process, such as glucose uptake by peripheral tissues, inhibition of hepatic gluconeogenesis and inhibition of lipolysis are all impaired, leading to elevated plasma glucose. Initially, the ?-cells are able to secrete enough insulin to compensate for this hyperglycemia and insulin levels at this time may appear normal to elevated (hyperinsulinemia). However, progressive ?-cell insulin secretory loss, the driving force in the progression from normal glucose tolerance to IGT to frank type 2 diabetes, eventually occurs leading to postprandial hyperglycemia and further loss of ?-cell functionality. The underlying cause of this loss is uncertain, but is most likely a combination of environmental/genetic factors and functional and anatomic defects, but interventions that improve glycemia can help offset the degree of ?-cell dysfunction. Hepatic glucose production also increases due to increased pancreatic ?-cell glucagon secretion. Eventually, the combination of increasing resistance, increasing hepatic glucose production and decreasing insulin secretion lead to fasting hyperglycemia as well as postprandial hyperglycemia.  -- Mechanisms of ?-Cell Death in Type 2 Diabetes

Incorrect

More Articles

September, 2016

  • 24 September

    Missing the Point

    iStock_000017571025_Small

    Friend of Diabetes in Control and frequent guest author David Kliff, Diabetic Investor, shared his views on some of the news coming out of EASD. As always, his ideas are thought-provoking. We reached out to some of our Advisory Board members to get their responses to David’s piece, and they provided additional strong viewpoints for your consideration.

    Read More »
  • 24 September

    Bio-Similar insulin for Lantus

    iStock_000050182656_Small

    When Lilly’s new Bio-Similar insulin for Lantus becomes available for maybe 20% less, will you let your patients know? Follow the link to share your opinion!

    Read More »
  • 20 September

    We Don’t All See the Same. See the World Through My Eyes

    iStock_000003296546_Small

    I received a call from a physician’s office regarding a patient who needed education as soon as possible. Her A1C had risen to 7.5 and at 64 years old, the patient needed to make changes. The only problem: the patient was blind. The patient lived alone with her Seeing Eye dog and was assisted by her brother. She lived a relatively normal life despite her blindness, working a clerical job and visiting the gym 2 days per week. As an educator, I had never dealt with a truly sightless individual and was feeling ill-equipped to take on this challenge. The majority of the diabetes patients in our small rural clinic have sight enough to manage their disease. I started to think of all the things we take for granted when teaching our patients, such as lancing their fingers, reading a label, even simply putting the correct amount of food on their plate. All that was thrown out the window. How did I help this patient to see her diabetes care?

    Read More »
  • 20 September

    Dr. Stanley Schwartz Part 4, Conference Anticipations

    stanley_schwartz

    In part 4 and the conclusion of this Exclusive Interview about the new diabetes classification, Dr. Schwartz highlights what he is looking forward to at the AACE and ADA conferences, particularly the results of the LEADER and GLP-1 studies.

    Read More »
  • 20 September

    Team-Based Approaches to Help Older Adults with T2 Achieve Individualized Glycemic Goals Part 4

    Mature on sofa measuring sugar level in blood using glucometer a

    In this week's Homerun Slides, the potential role of diabetes medications in the improved management of type 2 in older patients.

    Read More »
  • 20 September

    International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #42: Neuropeptides and Islet Hormone Secretion Part 1 of 5

    DeFronzoCover

    The traditional view is that islet hormone secretion is mainly regulated by circulating nutrients (glucose, amino acids, free fatty acids) as well as the gut incretin hormones (glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)). However, in certain circumstances regulation of insulin and glucagon secretion is also dependent on the autonomic nerves which innervate the islets. These nerves belong to the parasympathetic, sympathetic, and sensory branches of the autonomic nervous system.

    Read More »
  • 17 September

    Cardiovascular Mortality of Diabetes Medications

    Doctor Checking the Heart of a Senior Man

    What should be the proper treatment selection for patients with type 2 diabetes?

    Read More »
  • 17 September

    Metformin in Type 1 Patients Slows Development of Heart Disease

    type-1-diabetes

    Scientists believe drug commonly prescribed for T2 could be routinely taken by T1 patients.

    Read More »
  • 17 September

    Glycemic Benefits of Lixisenatide

    SONY DSC

    What benefits can lixisenatide provide when added to basal insulin regimen?

    Read More »
  • 17 September

    Empagliflozin and Long-Term Renal Effects

    Human kidney in abstract background

    Empagliflozin might not only decrease the risk of cardiovascular events in patients with type 2, but also renal events.

    Read More »
  • 17 September

    Evaluating the Role of Liraglutide in Type I Diabetes

    iStock_000045436892_Small

    Could GLP-1 inhibitors be a useful adjunct therapy in type I diabetes?

    Read More »
  • 17 September

    Adding Diasome’s HDV to Insulin

    iStock_000001089443_Small

    In Part 2 of this exclusive interview, Dr. Robert Geho discusses the Phase 2b study which focuses on adding Diasome's HDV to a leading pre-meal fast acting analogue.

    Read More »
  • 17 September

    The Role of the Liver in Type 1 Diabetes

    iStock_000012888324_Smallliver

    In part one of this exclusive interview, Dr. Robert Geho discusses the essential role of the liver in metabolizing insulin, and asks why we hear about the artificial pancreas all the time, but never hear anyone talk about an artificial liver?

    Read More »
  • 17 September

    Monitor Replacements

    iStock_000075170267_Small

    Do you agree that CGMS will eventually replace glucose monitors? Follow the link to share your opinion!

    Read More »
  • 17 September

    Video: Dr. Robert Geho, Diasome Insulin Additive

    In this Exclusive Interview, Dr. Robert Geho joins Diabetes in Control publisher Steve Freed at the 2016 Diabetes Symposium in Boston to discuss the testing, affects, and potential marketing of a new insulin delivery system currently undergoing trials. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc. ...

    Read More »